DSNKY:OTO-Daiichi Sankyo Co Ltd Sponsored ADR Level 1 (USD)

COMMON STOCK | Drug Manufacturers - General | OTC Pink

Last Closing

USD 35.86

Change

0.00 (0.00)%

Market Cap

USD 15.63B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Daiichi Sankyo Co Ltd., manufactures pharmaceuticals for human & veterinary use and medical tools and equipment. The Company also researches and promotes products through related companies.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZNCF AstraZeneca PLC

N/A

USD 240.18B
NVSEF Novartis AG

N/A

USD 208.10B
RHHBY Roche Holding Ltd ADR

N/A

USD 202.85B
RHHBF Roche Holding AG

N/A

USD 202.85B
RHHVF Roche Holding AG Participation

N/A

USD 202.50B
SNYNF Sanofi

N/A

USD 127.07B
GLAXF GSK plc

N/A

USD 92.19B
DSKYF Daiichi Sankyo Company Limited

N/A

USD 66.43B
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD 53.36B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 52.77B

ETFs Containing DSNKY

1638:TSE 13.34 % 0.00 %

N/A

N/A
JPCHBH:SW 1.58 % 0.00 %

N/A

N/A
JPUSBH:SW 1.58 % 0.00 %

N/A

N/A
JPEUBH:SW 1.57 % 0.00 %

N/A

N/A
UEF2:F 1.36 % 0.00 %

N/A

N/A
UEF2:XETRA 1.36 % 0.00 %

N/A

N/A
EJAH:F BNP Paribas Easy - MSCI J.. 0.00 % 0.00 %

N/A

USD 0.43B
SXR6:F iShares MSCI Japan SRI UC.. 0.00 % 0.00 %

N/A

USD 1.03B
JSRI:XETRA BNP Paribas Easy MSCI Jap.. 0.00 % 0.00 %

N/A

USD 0.44B
1473:TSE DIAM TOPIX 0.00 % 0.00 %

N/A

USD 583.54B
1474:TSE DIAM JPX Nikkei 400 0.00 % 0.00 %

N/A

USD 284.09B
1498:TSE AM-One ESG 0.00 % 0.00 %

N/A

USD 10.48B
1596:TSE NZAM TOPIX Ex-Financials 0.00 % 0.00 %

N/A

USD 2.99B
NADA:XETRA Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.12% 97% N/A 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.12% 97% N/A 83% B
Trailing 12 Months  
Capital Gain 3.55% 69% C- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.55% 67% D+ 62% D
Trailing 5 Years  
Capital Gain 108.09% 97% N/A 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 108.09% 91% A- 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 13.27% 91% A- 60% D-
Dividend Return 13.27% 76% C+ 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.01% 38% F 72% C
Risk Adjusted Return 44.22% 76% C+ 82% B
Market Capitalization 15.63B 81% B- 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.